NCT07614828撤回2 期
Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Malignant Melanoma of Nasal and Paranasal Mucosa
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 25
- 试验地点
- 1
研究概览
简要总结
Sinonasal mucosal malignant melanoma (SNMM) is a nasal and paranasal sinus malignancy with a low incidence and extremely poor prognosis, exhibiting specificity in Asian populations. For resectable SNMM, the efficacy of neoadjuvant immunotherapy is unclear. This prospective clinical study aims to explore the survival prognosis of neoadjuvant immunotherapy combing radiochemotherapy after Endoscopic Surgery for resectable SNMM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histopathologically confirmed diagnosis of malignant melanoma of the nasal cavity and paranasal sinuses.
- •T stage of T3 or T4a.
- •Age ≥18 years.
- •No distant metastasis.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, with general condition tolerating chemotherapy and general anesthesia for surgery.
- •Locally resectable with curative intent, and able to undergo contrast-enhanced CT or contrast-enhanced MRI examinations.
- •Adequate organ function: Hematology: white blood cells ≥3.0 × 10^9/L; absolute neutrophil count ≥1.5 × 10^9/L; hemoglobin ≥80 g/L; platelets ≥100 × 10^9/L. Hepatic function: total bilirubin ≤1.5 × upper limit of normal (ULN); AST and ALT ≤3 × ULN. Coagulation: international normalized ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5 × ULN. Renal function: serum creatinine ≤1.5 × ULN.
- •Patients with recurrence after prior curative surgery are allowed; for recurrent patients, chemotherapy and immune therapy must have been discontinued for more than 6 months.
排除标准
- •Patients who refuse to sign the informed consent form.
- •Patients with uncontrolled comorbidities that, in the investigator's judgment, would interfere with treatment.
- •Patients currently suffering from another malignant tumor or with synchronous multiple primary tumors that require treatment.
- •Patients with surgical contraindications, such as severe cardiopulmonary disease or coagulation disorders.
- •Patients with autoimmune diseases.
- •Patients currently using immunosuppressants, or receiving systemic glucocorticoids for immunosuppressive purposes (dose >10 mg/day prednisone or equivalent), and who continue to use them within 2 weeks prior to first dosing.
- •Prior treatment with PD-1 monoclonal antibodies or PD-L1 monoclonal antibodies; or a history of severe allergic reactions to other monoclonal antibodies.
- •Receipt of a live vaccine within 6 weeks prior to first dosing, or the possibility of receiving a live vaccine during the study.
- •Any condition that may compromise protocol adherence or safety during the study.
- •Uncontrolled active infection.
- •Pregnant or breastfeeding women.
- •Any other condition deemed unsuitable for enrollment.
研究组 & 干预措施
neoadjuvant immunotherapy combing radiochemotherapy before Endoscopic Surgery
Experimental
干预措施: neoadjuvant immunotherapy combing radiochemotherapy before Endoscopic Surgery (Drug)
研究者
Hongmeng Yu
Eye & ENT Hospital of Fudan University
Eye & ENT Hospital of Fudan University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver MetastasesNCT07277322Dan Feng24
招募中
2 期
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLNCT07380984Ruijin Hospital47
进行中（未招募）
不适用
Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast CancerBreast Cancer (Triple Negative Breast Cancer (TNBC))Breast CancerNCT07498400Xijing Hospital216
尚未招募
2 期
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCCNCT07400094National Medical Research Radiological Centre of the Ministry of Health of Russia50
尚未招募
2 期
Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaAdenoid Cystic CarcinomaNCT07616141Eye & ENT Hospital of Fudan University76